CA3065603A1 - Biomarqueur du cancer des ovaires et ses procedes d`utilisation - Google Patents

Biomarqueur du cancer des ovaires et ses procedes d`utilisation Download PDF

Info

Publication number
CA3065603A1
CA3065603A1 CA3065603A CA3065603A CA3065603A1 CA 3065603 A1 CA3065603 A1 CA 3065603A1 CA 3065603 A CA3065603 A CA 3065603A CA 3065603 A CA3065603 A CA 3065603A CA 3065603 A1 CA3065603 A1 CA 3065603A1
Authority
CA
Canada
Prior art keywords
ovarian cancer
arresten
expression
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065603A
Other languages
English (en)
Inventor
Mohammad R. Akbari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Women's College Hospital
Original Assignee
Women's College Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Women's College Hospital filed Critical Women's College Hospital
Priority to CA3065603A priority Critical patent/CA3065603A1/fr
Priority to US17/121,012 priority patent/US20210181200A1/en
Publication of CA3065603A1 publication Critical patent/CA3065603A1/fr
Priority to US17/842,373 priority patent/US20220390453A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3065603A 2019-12-17 2019-12-17 Biomarqueur du cancer des ovaires et ses procedes d`utilisation Pending CA3065603A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3065603A CA3065603A1 (fr) 2019-12-17 2019-12-17 Biomarqueur du cancer des ovaires et ses procedes d`utilisation
US17/121,012 US20210181200A1 (en) 2019-12-17 2020-12-14 Ovarian cancer biomarker and methods of using same
US17/842,373 US20220390453A1 (en) 2019-12-17 2022-06-16 Ovarian cancer biomarker and methods of using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3065603A CA3065603A1 (fr) 2019-12-17 2019-12-17 Biomarqueur du cancer des ovaires et ses procedes d`utilisation

Publications (1)

Publication Number Publication Date
CA3065603A1 true CA3065603A1 (fr) 2021-06-17

Family

ID=76433076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065603A Pending CA3065603A1 (fr) 2019-12-17 2019-12-17 Biomarqueur du cancer des ovaires et ses procedes d`utilisation

Country Status (1)

Country Link
CA (1) CA3065603A1 (fr)

Similar Documents

Publication Publication Date Title
Leung et al. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients
Sandri et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome
Molina et al. Tumor markers in breast cancer–European Group on Tumor Markers recommendations
Duffy et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
Yie et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse
Chudecka-Głaz et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer
US20110053156A1 (en) Small cell lung carcinoma biomarker panel
Wang et al. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer
JP6216732B2 (ja) 癌の診断方法ならびに癌患者の全生存期間および無病生存期間の決定方法
WO2022063156A1 (fr) Biomarqueur du cancer du sein et son application
CN101421622A (zh) 作为癌症生物标志物的游离ngal
Yin et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer
Xu et al. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma
Sun et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma
US9684001B2 (en) Biomarkers for head-and-neck cancers and precancers
CN109975549A (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
Amirghofran et al. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis
Karlikova et al. Evaluation of serum cytokeratines, thymidine kinase, and growth factors as cancer biomarkers in colorectal cancer
US20210181200A1 (en) Ovarian cancer biomarker and methods of using same
US20220390453A1 (en) Ovarian cancer biomarker and methods of using same
CA3065603A1 (fr) Biomarqueur du cancer des ovaires et ses procedes d`utilisation
Manule et al. Prognostic value of β-catenin and L1CAM expressions in type I endometrial carcinoma
US20070269831A1 (en) Method for Early Detection of Ovarian Cancer
Setianingsih et al. Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder cancer
CA3163199A1 (fr) Biomarqueur du cancer des ovaires et ses procedes d~utilisation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241113

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241113

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250610